Home > Boards > US Listed > Biotechs >

Enanta Pharmaceuticals (ENTA)

ENTA RSS Feed
Add ENTA Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 5/19/2022 8:56:12 PM - Followers: 81 - Board type: Free - Posts Today: 0
ENTA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ENTA News: Evercore ISI Maintains a Sell Rating on Enanta Pharmaceuticals (ENTA) 05/19/2022 07:46:15 PM
ENTA News: JMP Securities Reaffirms Their Buy Rating on Enanta Pharmaceuticals (ENTA) 05/18/2022 08:45:13 PM
ENTA News: Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV) 05/18/2022 12:01:00 PM
ENTA News: Enanta Pharmaceuticals (ENTA) Receives a Hold from SVB Securities 05/10/2022 04:44:47 AM
ENTA News: Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Precision BioSciences (DTIL) 05/09/2022 10:15:15 PM
PostSubject
#2244  Sticky Note New corporate slide set (5/18/22): DewDiligence 05/19/22 01:38:37 PM
#2246   Thanks Dew. The second to last slide (#29) vinmantoo 05/19/22 08:56:12 PM
#2245   Follow-up—After all the commotion, ENTA closed down only DewDiligence 05/19/22 06:03:10 PM
#2244   New corporate slide set (5/18/22): DewDiligence 05/19/22 01:38:37 PM
#2243   On the heels of this disappointing RSV trial, vinmantoo 05/19/22 11:43:24 AM
#2242   ENTA’s phase-2b trial in RSV misses primary endpoint: vinmantoo 05/19/22 01:56:07 AM
#2241   ENTA’s valuation: DewDiligence 05/18/22 06:37:04 PM
#2239   Thoughts? JK2016 05/18/22 04:13:31 PM
#2238   ENTA’s phase-2b trial in RSV misses primary endpoint: DewDiligence 05/18/22 04:09:41 PM
#2237   NIH wants_to_study longer treatment_course for Paxlovid: vinmantoo 05/18/22 12:54:49 PM
#2236   NIH wants_to_study longer treatment_course for Paxlovid: DewDiligence 05/18/22 12:48:57 PM
#2235   @George Rho vinmantoo 05/18/22 12:41:36 PM
#2234   I added last week at about $50.00 vinmantoo 05/18/22 12:34:55 PM
#2233   I added last week at about $50.00 willyw 05/18/22 11:07:36 AM
#2232   Out of Ignorance profile picture willyw 05/18/22 10:45:41 AM
#2231   George Rho profile picture willyw 05/18/22 10:44:58 AM
#2230   A very worthwhile reply to the article is DewDiligence 05/18/22 10:36:44 AM
#2229   https://seekingalpha.com/article/4512678-enanta-slow-drip A very worth while willyw 05/18/22 10:34:35 AM
#2227   Thoughts on this post on “seeking alpha” “Enanta: Slow JK2016 05/18/22 08:43:19 AM
#2226   ENTA’s enterprise value at the current share price vinmantoo 05/17/22 09:05:44 PM
#2225   ENTA’s enterprise value at the current share price DewDiligence 05/11/22 07:02:30 PM
#2224   ENTA’s fully-diluted share count @3/31/22=24.7M—unchanged since 12/31/21 DewDiligence 05/11/22 06:58:02 PM
#2223   ENTA’s pro forma cash @3/31/22=$353.3M—a decrease of $24.4M DewDiligence 05/11/22 06:57:35 PM
#2222   The main difference between the latest slide set DewDiligence 05/10/22 03:30:20 PM
#2221   I too noticed the lack of a meaningful DewDiligence 05/10/22 12:59:05 PM
#2220   Thanks Dew. vinmantoo 05/10/22 12:47:10 PM
#2218   ENTA new corporate slide set (5/9/22): DewDiligence 05/10/22 11:31:29 AM
#2217   ENTA FY2Q22 CC transcript: DewDiligence 05/10/22 11:29:19 AM
#2216   ENTA FY2Q22* financials—royalty_revenue=$18.7M—3/31/22_cash=$322.5M (down from $ DewDiligence 05/09/22 04:06:52 PM
#2215   Paxlovid misses primary endpoint in post-exposure prophylaxis: DewDiligence 04/29/22 06:31:44 PM
#2214   Thanks. willyw 04/29/22 01:25:09 PM
#2213   He’s using the word, inoculation to mean infection DewDiligence 04/29/22 01:19:19 PM
#2212   I'm still just trying to unpack the first tweet?!? willyw 04/29/22 01:05:28 PM
#2211   Sounds like he's confused; he has a lot DewDiligence 04/29/22 11:30:15 AM
#2210   If you think about the body as consisting vinmantoo 04/29/22 10:33:02 AM
#2209   Use of a P-glycoprotein inhibitor (https://twitter.com/Biohazard3737/status/1519 DewDiligence 04/29/22 08:15:26 AM
#2208   What technical details? vinmantoo 04/29/22 08:03:45 AM
#2207   It seems to me that @Biohazard3737 (“Sheep of DewDiligence 04/28/22 12:45:07 PM
#2206   I read the guy’s dismissal of EDP-235 and vinmantoo 04/28/22 12:15:56 PM
#2204   My two replies (one re RSV and one DewDiligence 04/28/22 10:40:16 AM
#2203   And what were your replies to those comments? JK2016 04/28/22 10:32:36 AM
#2202   Tweet thread from a short: DewDiligence 04/27/22 02:31:53 PM
#2201   Shionogi PR re COVID antiviral fails to mention teratogenicity! DewDiligence 04/25/22 10:23:37 AM
#2200   Wow, ENTA has been a roller coaster recently. vinmantoo 04/21/22 04:33:40 PM
#2199   Some_patients_may_need_longer_treatment_course_of Paxlovid, according_ to_anecdotal_info: DewDiligence 04/21/22 04:31:48 PM
#2198   Ascletis’ ASC11 could be a serious competitor to DewDiligence 04/19/22 09:46:01 AM
#2197   Thoughts on the news from ASCLF today on JK2016 04/19/22 09:25:06 AM
#2196   XBI was -4.8%, so today’s selloff was not ENTA-specific. DewDiligence 04/18/22 05:39:06 PM
#2195   Why the purge today? Yikes. JK2016 04/18/22 03:42:36 PM
#2194   One fewer serious competitor for EDP-235. DewDiligence 04/13/22 10:18:51 AM
#2193   https://www.bloomberg.com/news/articles/2022-04-13/shionogi-falls-most-in-decade-on-birth-defect-ris willyw 04/13/22 08:43:47 AM
PostSubject
Consent Preferences